AAPL315.94-4.03 (-1.26%) ▼|ABBV251.02-5.44 (-2.12%) ▼|ABT105.72-2.61 (-2.41%) ▼|ACN178.68-8.05 (-4.31%) ▼|ADBE257.90-8.61 (-3.23%) ▼|AMAT470.10+15.39 (+3.38%) ▲|AMD508.05+30.48 (+6.38%) ▲|AMGN395.81-41.42 (-9.47%) ▼|AMT177.45+1.60 (+0.91%) ▲|AMZN257.21-1.30 (-0.50%) ▼|AVGO371.22+13.32 (+3.72%) ▲|AXP327.57+1.41 (+0.43%) ▲|BA215.19+2.94 (+1.39%) ▲|BAC62.65-0.04 (-0.06%) ▼|BKNG182.48-10.81 (-5.59%) ▼|BLK1,106.10-10.46 (-0.94%) ▼|BMY65.01-1.81 (-2.71%) ▼|BNY164.30-0.55 (-0.33%) ▼|BRK-B504.34-1.69 (-0.33%) ▼|C137.64-0.09 (-0.06%) ▼|CAT828.40+14.46 (+1.78%) ▲|CL88.20-0.57 (-0.64%) ▼|CMCSA26.15-0.35 (-1.30%) ▼|COF216.29-3.32 (-1.51%) ▼|COP135.48+1.22 (+0.91%) ▲|COST907.74-8.01 (-0.87%) ▼|CRM250.47-8.77 (-3.38%) ▼|CSCO109.38+0.18 (+0.16%) ▲|CVS95.76-0.98 (-1.02%) ▼|CVX211.10+2.50 (+1.20%) ▲|DE683.73-9.80 (-1.41%) ▼|DHR205.78-1.88 (-0.91%) ▼|DIS104.56-0.75 (-0.71%) ▼|DUK121.17+0.95 (+0.79%) ▲|EMR153.67+0.85 (+0.56%) ▲|FDX318.85-3.67 (-1.14%) ▼|GD356.23-3.17 (-0.88%) ▼|GE338.87+1.75 (+0.52%) ▲|GEV961.23+19.28 (+2.05%) ▲|GILD146.16-4.84 (-3.20%) ▼|GM85.74-2.02 (-2.30%) ▼|GOOG335.45+0.14 (+0.04%) ▲|GOOGL338.53+0.07 (+0.02%) ▲|GS1,039.75+1.14 (+0.11%) ▲|HD317.30-3.75 (-1.17%) ▼|HON208.59-1.02 (-0.49%) ▼|IBM232.56-2.33 (-0.99%) ▼|INTC104.17+8.37 (+8.74%) ▲|INTU314.87-17.83 (-5.36%) ▼|ISRG350.35-16.35 (-4.46%) ▼|JNJ267.95-7.28 (-2.65%) ▼|JPM356.50-2.15 (-0.60%) ▼|KO87.91-0.16 (-0.18%) ▼|LIN470.26-7.31 (-1.53%) ▼|LLY1,119.32-30.04 (-2.61%) ▼|LMT540.95+15.67 (+2.98%) ▲|LOW202.44-2.02 (-0.99%) ▼|LRCX321.09+13.44 (+4.37%) ▲|MA568.31-10.91 (-1.88%) ▼|MCD255.65-0.04 (-0.02%) ▼|MDLZ60.97-0.31 (-0.51%) ▼|MDT91.82-2.35 (-2.50%) ▼|META616.72-0.05 (-0.01%) ▼|MMM166.26-2.30 (-1.36%) ▼|MO67.93-0.95 (-1.38%) ▼|MRK148.31-2.02 (-1.34%) ▼|MS218.05+0.33 (+0.15%) ▲|MSFT492.98-6.72 (-1.34%) ▼|MU1,019.25+2.66 (+0.26%) ▲|NEE84.09+0.66 (+0.79%) ▲|NFLX76.62-1.63 (-2.09%) ▼|NKE38.17-0.24 (-0.61%) ▼|NOW135.35-5.91 (-4.18%) ▼|NVDA226.66-3.70 (-1.61%) ▼|ORCL164.53+5.75 (+3.62%) ▲|PEP137.98+0.35 (+0.25%) ▲|PFE27.87-0.58 (-2.04%) ▼|PG144.69-1.75 (-1.20%) ▼|PLTR171.34-2.99 (-1.72%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|AAPL315.94-4.03 (-1.26%) ▼|ABBV251.02-5.44 (-2.12%) ▼|ABT105.72-2.61 (-2.41%) ▼|ACN178.68-8.05 (-4.31%) ▼|ADBE257.90-8.61 (-3.23%) ▼|AMAT470.10+15.39 (+3.38%) ▲|AMD508.05+30.48 (+6.38%) ▲|AMGN395.81-41.42 (-9.47%) ▼|AMT177.45+1.60 (+0.91%) ▲|AMZN257.21-1.30 (-0.50%) ▼|AVGO371.22+13.32 (+3.72%) ▲|AXP327.57+1.41 (+0.43%) ▲|BA215.19+2.94 (+1.39%) ▲|BAC62.65-0.04 (-0.06%) ▼|BKNG182.48-10.81 (-5.59%) ▼|BLK1,106.10-10.46 (-0.94%) ▼|BMY65.01-1.81 (-2.71%) ▼|BNY164.30-0.55 (-0.33%) ▼|BRK-B504.34-1.69 (-0.33%) ▼|C137.64-0.09 (-0.06%) ▼|CAT828.40+14.46 (+1.78%) ▲|CL88.20-0.57 (-0.64%) ▼|CMCSA26.15-0.35 (-1.30%) ▼|COF216.29-3.32 (-1.51%) ▼|COP135.48+1.22 (+0.91%) ▲|COST907.74-8.01 (-0.87%) ▼|CRM250.47-8.77 (-3.38%) ▼|CSCO109.38+0.18 (+0.16%) ▲|CVS95.76-0.98 (-1.02%) ▼|CVX211.10+2.50 (+1.20%) ▲|DE683.73-9.80 (-1.41%) ▼|DHR205.78-1.88 (-0.91%) ▼|DIS104.56-0.75 (-0.71%) ▼|DUK121.17+0.95 (+0.79%) ▲|EMR153.67+0.85 (+0.56%) ▲|FDX318.85-3.67 (-1.14%) ▼|GD356.23-3.17 (-0.88%) ▼|GE338.87+1.75 (+0.52%) ▲|GEV961.23+19.28 (+2.05%) ▲|GILD146.16-4.84 (-3.20%) ▼|GM85.74-2.02 (-2.30%) ▼|GOOG335.45+0.14 (+0.04%) ▲|GOOGL338.53+0.07 (+0.02%) ▲|GS1,039.75+1.14 (+0.11%) ▲|HD317.30-3.75 (-1.17%) ▼|HON208.59-1.02 (-0.49%) ▼|IBM232.56-2.33 (-0.99%) ▼|INTC104.17+8.37 (+8.74%) ▲|INTU314.87-17.83 (-5.36%) ▼|ISRG350.35-16.35 (-4.46%) ▼|JNJ267.95-7.28 (-2.65%) ▼|JPM356.50-2.15 (-0.60%) ▼|KO87.91-0.16 (-0.18%) ▼|LIN470.26-7.31 (-1.53%) ▼|LLY1,119.32-30.04 (-2.61%) ▼|LMT540.95+15.67 (+2.98%) ▲|LOW202.44-2.02 (-0.99%) ▼|LRCX321.09+13.44 (+4.37%) ▲|MA568.31-10.91 (-1.88%) ▼|MCD255.65-0.04 (-0.02%) ▼|MDLZ60.97-0.31 (-0.51%) ▼|MDT91.82-2.35 (-2.50%) ▼|META616.72-0.05 (-0.01%) ▼|MMM166.26-2.30 (-1.36%) ▼|MO67.93-0.95 (-1.38%) ▼|MRK148.31-2.02 (-1.34%) ▼|MS218.05+0.33 (+0.15%) ▲|MSFT492.98-6.72 (-1.34%) ▼|MU1,019.25+2.66 (+0.26%) ▲|NEE84.09+0.66 (+0.79%) ▲|NFLX76.62-1.63 (-2.09%) ▼|NKE38.17-0.24 (-0.61%) ▼|NOW135.35-5.91 (-4.18%) ▼|NVDA226.66-3.70 (-1.61%) ▼|ORCL164.53+5.75 (+3.62%) ▲|PEP137.98+0.35 (+0.25%) ▲|PFE27.87-0.58 (-2.04%) ▼|PG144.69-1.75 (-1.20%) ▼|PLTR171.34-2.99 (-1.72%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|
25.3 C
New York
Tuesday, September 8, 2026

Tag: products

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...

Zepp Health Corporation Reports Second Quarter 2025 Unaudited Financial Results

MILPITAS, Calif., Aug. 3, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaudited financial results for the...

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities...

SAN DIEGO, Aug. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.).

Eliquid Base Launches Compliant Prefilled Pod Kit as Legal Alternative to Banned Disposable Vapes in the UK

MANCHESTER, United Kingdom, Aug. 03, 2025 (GLOBE NEWSWIRE) -- With the UK government's 2025 disposable vape ban now in effect to tackle environmental concerns and reduce health risks, millions of vapers are left seeking legal and reliable alternatives. Eliquid Base, one of the UK's leading online vape retailers, has stepped up with a robust solution; the launch of compliant prefilled pod kits that align with UK TPD regulations, offering the same convenience and flavour experience as disposables without breaching the new rules.

United Imaging Teases Multi-modality “Provider Success” Product Launches at AHRA 2025

The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting in Las Vegas. HOUSTON, Aug. 3, 2025...

Bitcoin Swift Opens Final 5 Days of Stage 3 Presale With Real-Time Passive Yield and Zero Lockups

LUXEMBOURG, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a programmable passive yield protocol, has entered the final five days of Stage 3 in its 64-day presale, which is set to end on September 18, 2025. The current price of BTC3 stands at $3, with Stage 4 expected to increase to $4. BTC3 is confirmed to list at $15 on Orca DEX (orca.so).

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

Pilly Labs Aligns with 2025 Demand for the Best Nutritional Gummies Supporting Whole Body Wellness

In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality.
In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality.

Pilly Labs Formulates 2025’s Top Mushroom Extract Gummies Supplement for ADHD Focus, Anxiety Support, and Natural Weight Wellness

As 2025 consumers increasingly seek natural ways to support attention, emotional balance, and metabolic wellness, Pilly Labs introduces a fruiting body mushroom gummy blend featuring Lion’s Mane, Reishi, and Cordyceps—positioned at the intersection of convenience, cognitive clarity, and ingredient transparency.
As 2025 consumers increasingly seek natural ways to support attention, emotional balance, and metabolic wellness, Pilly Labs introduces a fruiting body mushroom gummy blend featuring Lion’s Mane, Reishi, and Cordyceps—positioned at the intersection of convenience, cognitive clarity, and ingredient transparency.

Collagen Supplement Trends in 2025: Why Pilly Labs Collagen Gummies Are Leading the Natural Glow-Up Movement

As consumer demand for clean beauty and functional supplements rises in 2025, marine collagen gummies like Pilly Labs are emerging as a preferred daily solution for supporting skin texture, joint mobility, and hair strength — all without powders, pills, or synthetic additives.
As consumer demand for clean beauty and functional supplements rises in 2025, marine collagen gummies like Pilly Labs are emerging as a preferred daily solution for supporting skin texture, joint mobility, and hair strength — all without powders, pills, or synthetic additives.

Chaga Mushroom Supplement Surge: Why Pilly Labs’ 2025 Formula Is Reshaping Immune Health Conversations

Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.
Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.

Mushroom Gummies vs Chaga Mushrooms: Why Pilly Labs Is Leading the Functional Supplement Shift in 2025

As consumers search for natural alternatives to support focus, immune resilience, and metabolic balance, mushroom gummies are rapidly emerging as a preferred delivery method—especially in 2025’s ingredient-first supplement movement led by fruiting body extracts like Chaga, Lion’s Mane, and Cordyceps.
As consumers search for natural alternatives to support focus, immune resilience, and metabolic balance, mushroom gummies are rapidly emerging as a preferred delivery method—especially in 2025’s ingredient-first supplement movement led by fruiting body extracts like Chaga, Lion’s Mane, and Cordyceps.

The Survival Starter Plan by My Patriot Supply: Emergency Food, Clean Water, Off-Grid Power, and Heat Solutions for 2025 Crisis Readiness

Build real-world resilience with a simple, category-based system that covers emergency food, portable water filtration, solar power, and off-grid heating—designed for modern families facing blackouts, disasters, or disruptions in 2025.
Build real-world resilience with a simple, category-based system that covers emergency food, portable water filtration, solar power, and off-grid heating—designed for modern families facing blackouts, disasters, or disruptions in 2025.

Feel Good Knees Introduces “Knee Self-Restoration Ritual” Backed by Stanford Orthopedic Research on Natural Cartilage Healing

New 5-Minute Routine May Help Naturally Support Knee Cartilage Health, Flexibility, and Joint Comfort at Any Age
New 5-Minute Routine May Help Naturally Support Knee Cartilage Health, Flexibility, and Joint Comfort at Any Age

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProducts